Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Bavarian Nordic A/S

+ Add to Watchlist

BV3:GR

47.725 EUR 1.825 3.98%

As of 14:20:36 ET on 03/27/2015.

Snapshot for Bavarian Nordic A/S (BV3)

Open: 44.316 Day's Range: 44.316 - 48.415 Volume: 358
Previous Close: 45.900 52wk Range: 12.490 - 50.017 1-Yr Rtn: +263.48%

Stock Chart for BV3

No chart data available.
  • BV3:GR 47.725
  • 1D
  • 1M
  • 1Y
45.900
Interactive BV3 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BV3

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 65.1214
Relative P/E vs. DAX -
Earnings Per Share (DKK) (ttm) -
Est. EPS (DKK) (12/2015) 5.4730
Est. PEG Ratio -
Market Cap (M EUR) 1,323.51
Shares Outstanding (M) 27.73
30 Day Average Volume 578
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BV3

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for BV3

Bavarian Nordic A/S is a biotechnology company developing and producing vaccines for the treatment and prevention of cancer and infectious diseases. The company also manufactures and delivers modern smallpox vaccines for governments under national emergency rules.

Paul ChaplinPresident/CEOJames B Breitmeyer "Jim"Exec VP/Chief Development Officer
Ole LarsenExec VP/CFORolf Sass SoerensenVP:Investor Relations
More Company Profile & Key Executives for BV3

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil